Alexiev Ivailo, Shankar Anupama, Dimitrova Reneta, Gancheva Anna, Kostadinova Asia, Teoharov Pavel, Golkocheva Elitsa, Nikolova Maria, Muhtarova Mariya, Elenkov Ivaylo, Stoycheva Mariyana, Nikolova Daniela, Varleva Tonka, Switzer William M
National Reference Laboratory of HIV, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
Laboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Infect Genet Evol. 2016 Dec;46:269-278. doi: 10.1016/j.meegid.2016.05.029. Epub 2016 May 21.
Increased HIV transmission in persons who inject drugs (PWIDs) has led to subepidemics and outbreaks in several countries in Europe, including Bulgaria. In this study in Bulgaria, we investigate the origin and spatiotemporal evolutionary history of HIV-1 infections in PWIDs and the distribution of antiretroviral resistance mutations and hepatitis co-infections in these populations. We analyzed HIV-1 polymerase sequences available from 117 of 359 PWIDs diagnosed with HIV/AIDS from 1999 to 2011. Of these, 50 (42.7%) were classified as CRF02_AG, 41 (35.0%) CRF01_AE, 12 (10.3%) URFs, ten (8.5%) subtype B, two (1.7%) subtype F1 and two (1.7%) CRF14_BG. Most recent common ancestor dating suggests that CRF01_AE was likely first introduced from Southeast Asia into persons reporting heterosexual infection in Bulgaria in 1992 and spread subsequently to PWIDs in the capital city of Sofia around 2003. Conversely, CRF02_AG in Bulgaria was likely first introduced into PWID from Germany in 2000 and later entered heterosexual populations around 2009. The overall prevalence of resistance mutations was 6.8% (8/117), of which 5.1% (5/117) was observed in patients on antiretroviral therapy and 1.7% (2/117) was from transmitted drug resistance mutations in drug-naïve individuals. 189/204 (92.6%) PWIDs were also co-infected with hepatitis C (HCV) and 31/183 (16.9%) were co-infected with hepatitis B (HBV). Our study provides valuable molecular epidemiological information on the introduction and distribution of the main HIV-1 subtypes, resistance mutations and hepatitis co-infections among PWIDs with HIV-1 in Bulgaria which can be used to target prevention efforts.
注射吸毒者(PWID)中艾滋病毒传播的增加已在包括保加利亚在内的欧洲多个国家引发了局部流行和疫情爆发。在保加利亚的这项研究中,我们调查了注射吸毒者中HIV-1感染的起源和时空演变历史,以及这些人群中抗逆转录病毒耐药突变和肝炎合并感染的分布情况。我们分析了1999年至2011年期间诊断为艾滋病毒/艾滋病的359名注射吸毒者中117人的HIV-1聚合酶序列。其中,50例(42.7%)被归类为CRF02_AG,41例(35.0%)为CRF01_AE,12例(10.3%)为URF,10例(8.5%)为B亚型,2例(1.7%)为F1亚型,2例(1.7%)为CRF14_BG。最近共同祖先追溯表明,CRF01_AE可能于1992年首次从东南亚传入保加利亚报告异性感染的人群,并随后于2003年左右传播到首都索非亚的注射吸毒者中。相反,保加利亚的CRF02_AG可能于2000年首次从德国传入注射吸毒者中,随后于2009年左右进入异性恋人群。耐药突变的总体流行率为6.8%(8/117),其中5.1%(5/117)在接受抗逆转录病毒治疗的患者中观察到,1.7%(2/117)来自未接受过治疗的个体的传播性耐药突变。189/204(92.6%)的注射吸毒者还合并感染了丙型肝炎(HCV),31/183(16.9%)合并感染了乙型肝炎(HBV)。我们的研究提供了关于保加利亚感染HIV-1的注射吸毒者中主要HIV-1亚型的引入和分布、耐药突变以及肝炎合并感染的有价值的分子流行病学信息,可用于指导预防工作。